Projects

View
Name EMIF
Long Name European Medical Information Framework
Description European Medical Information Framework. The EMIF project aims to develop a common information framework of patient-level data that will link up and facilitate access to diverse medical and research data sources, opening up new avenues of research for scientists. To provide a focus and guidance for the development of the framework, the project will focus initially on questions relating to obesity and Alzheimer’s disease.
Objectives 1. To establish an information framework to improve access to human health data by providing tools and workflows to discover, assess, access, and (re)use human health data. 2. To identify predictors and diagnostic biomarkers for Alzheimer’s Disease. 3. To identify predictors of metabolic complications in obesity.
Website http://www.emif.eu/
Start date 01-01-2013
End date 30-06-2018
Logo
Name Projects Type of institution Country  
Synapse Research Management Partners SL EPAD AMYPAD NEURONET EMIF ROADMAP SME Spain
Janssen Pharmaceutica NV EPAD ADAPTED AMYPAD IMPRiND EQIPD NEURONET EMIF IM2PACT PHAGO PRISM RADAR-CNS RADAR-AD ROADMAP IDEA-FAST Pharma-Cog EPND EFPIA Belgium
Alzheimer Europe EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD ROADMAP NEURONET Pharma-Cog EPND Patient/carers organisation Luxembourg
F. Hoffmann-La Roche AG EPAD EQIPD EMIF PHAGO PRISM ROADMAP NEURONET IDEA-FAST Pharma-Cog EPND EFPIA Switzerland
Amgen EPAD EMIF Mobilise-D EFPIA Belgium
Pfizer Limited EPAD EQIPD EMIF IM2PACT PRISM Mobilise-D IDEA-FAST EFPIA United Kingdom
UCB Biopharma SPRL EPAD EQIPD AETIONOMY EMIF PD-MitoQUANT RADAR-CNS IDEA-FAST Pharma-Cog EPND EFPIA Belgium
Institut National De La Sante Et De La Recherche Medicale EPAD EMIF Pharma-Cog Academia France
Karolinska Institutet EPAD AMYPAD MOPEAD AETIONOMY EMIF RADAR-AD Academia Sweden
VU University Medical Center Amsterdam EPAD AMYPAD IM2PACT PRISM MOPEAD RADAR-CNS RADAR-AD EMIF PRISM2 Pharma-Cog EPND Academia Netherlands
University Of Cambridge EPAD IMPRiND PHAGO EMIF IDEA-FAST Academia United Kingdom
University Of Oxford EPAD IMPRiND IM2PACT RADAR-AD ROADMAP EMIF EPND Academia United Kingdom
University Of Leicester EPAD EMIF EPND Academia United Kingdom
Boehringer Ingelheim International Gmbh PRISM EPAD EQIPD AETIONOMY EMIF Pharma-Cog PRISM2 EFPIA Germany
Erasmus Universitair Medisch Centrum Rotterdam PRISM ADAPTED AETIONOMY EMIF ROADMAP EPAD IDEA-FAST Academia Netherlands
University Of Exeter PRISM EMIF PD-MIND Pharma-Cog Academia United Kingdom
Concentris Research Management GmbH PRISM EQIPD EMIF PRISM2 SME Germany
Institut De Recherches Servier IMPRiND EMIF EQIPD Pharma-Cog Academia France
Aarhus Universitet IMPRiND IM2PACT ROADMAP EMIF Academia Denmark
Vib Center for Brain and Disease Research IMPRiND EMIF Academia Belgium
Merck Kommanditgesellschaft Auf Aktien EMIF Mobilise-D Pharma-Cog EFPIA Germany
Novo Nordisk AS IM2PACT EMIF EFPIA Denmark
University College London AMYPAD PD-MitoQUANT PHAGO EMIF Academia United Kingdom
Kobenhavns Universitet IM2PACT ROADMAP EMIF Academia Denmark
Goeteborgs Universitet PHAGO ROADMAP EMIF EPND Academia Sweden
King's College London PHAGO RADAR-CNS RADAR-AD EMIF PD-MIND EPND Academia United Kingdom
Provincia Lombardo Veneta - Ordineospedaliero Di San Giovanni Di Dio - Fatebenefratelli RADAR-CNS EMIF Pharma-Cog Academia Italy
Fundacio Institut Universitari Per a La Recerca A L'Atencio Primaria De Salut Jordi Gol i Gurina ROADMAP EMIF Academia Spain
Universiteit Maastricht ROADMAP EMIF EPND Academia Netherlands
Glaxosmithkline Research And Development Ltd EMIF Pharma-Cog EFPIA United Kingdom
Agenzia Regionale Di Sanita EMIF Academia Italy
European Institute For Health Records EMIF Academia France
European Molecular Biology Laboratory EMIF Academia Germany
Fondazione PENTA for The Treatment And Care Of Children With HIV-ONLUS EMIF Academia Italy
Itä-Suomen Yliopisto/University of Eastern Finland EMIF Academia Finland
Leibniz-Institut Für Präventionsforschung Und Epidemiologie - BIPS GmbH EMIF Academia Germany
Sorbonne Université/Université Pierre et Marie Curie EMIF Academia France
Tartu Ulikool EMIF Academia Estonia
Teknologian Tutkimuskeskus VTT Oy EMIF IDEA-FAST Academia Finland
University Of Manchester EMIF Academia United Kingdom
Universitat Pompeu Fabra EMIF Academia Spain
Universidade De Aveiro EMIF Academia Portugal
Universita di Pisa EMIF Academia Italy
Universitatsklinikum Erlangen EMIF Mobilise-D Academia Germany
Universiteit Antwerpen EMIF Academia Belgium
University Of Glasgow EMIF IDEA-FAST Academia United Kingdom
University Of Helsinki EMIF Academia Finland
University Of Luebeck EMIF Academia Germany
Universität Leipzig EMIF Pharma-Cog Academia Germany
Cambridge Cognition Ltd EMIF IDEA-FAST SME United Kingdom
Custodix NV EMIF SME Belgium
Electrophoretics Ltd EMIF SME United Kingdom
Genomedics SRL EMIF SME Italy
MAAT France EMIF SME France
Societa Servizi Telematici SRL EMIF SME Italy
Stichting Informatievoorziening Voor Zorg En Onderzoek EMIF SME Netherlands
Vestische Kinder und Jugendklinik EMIF Academia Germany
PHARMO Institute NV EMIF SME Netherlands
Universite Paul Sabatier Toulouse III EMIF Pharma-Cog Academia France
Universitätsklinikum Schleswig-Holstein EMIF IDEA-FAST Academia Germany
WP number Description Project  
WP1 Definition of study population data requirements and data collection EMIF
WP2 Characterisation of the study population and definition of extreme phenotypes EMIF
WP3 Biomarker discovery EMIF
WP4 Validation of new biomarkers and identification and selection of individuals for pharmacological interventions EMIF
WP5 Use carefully characterized extreme phenotypes to identify biomarkers of metabolic risk EMIF
WP6 The investigation of heterogeneity in the metabolic consequences of obesity in medium-sized well phenotyped cohort studies EMIF
WP7 Validate novel risk factors in general population in adults and children EMIF
WP8 Identify and select individuals for pharmacological or non-pharmacological interventions EMIF
WP9 Framework requirements and evaluation EMIF
WP10 Governance, federation, DB fingerprinting, legal context and ethics EMIF
WP11 Harmonisation and semantics EMIF
WP13 Analysis, processing and visualisation methods and tools EMIF
WP14 Architecture, solution development, security and privacy technologies EMIF
WP15 Use and sustainability models, community building and outreach EMIF
WP16 Project Management EMIF
WP12 Data extraction, benchmarking, Data aggregation and linkage EMIF
Deliverable number Title Project Submission date Link Keywords  
D1.1 Overview of available data sources EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d1_1_overview_available_data_exec_summary_website.pdf
D1.2 Private Remote Research database environment with pooled data from research cohorts EMIF 30-06-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d1_2_prre_research_cohorts_exec_summary_website.pdf
D1.3 Dataset with EHR data linked to research cohort data EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d1.3_dataset-with-ehr-data-linked-to-research-cohort-data.pdf
D1.4 Cohort of cognitively normal subjects with AD biomarkers baseline data EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d1.4_cohort-of-cognitively-normal-subjects-with-ad-biomarkers-baseline-data.pdf
D1.5 Cohort of cognitively normal subjects with 2-year follow-up data EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d1.5_cohort-of-cognitively-normal-subjects-with-2year-followup-data.pdf
D2.1 Summary statistics of cohorts included EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d2_1_summary_statistics_exec_summary_website.pdf
D2.2 Validated criteria for presymptomatic AD and prodromal AD EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d2_2_criteria_presymptomatic_prodromal_ad_exec_summary_website.pdf
D2.3 Definition of extreme phenotypes based on cognitive decline EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d2_3_extreme_phenotypes_cognitive_decline_exec_summary_website.pdf
D2.4 Prediction model for cognitive decline EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d2_4_prediction_model_cognitive_decline_exec_summary_website.pdf
D2.5 Definition of extreme phenotypes based on AD biomarkers EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d2_5_extreme_phenotypes_ad_biomarkers_exec_summary_website.pdf
D2.6 Definition of extreme phenotypes based on resilience to dementia EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d2.6_definition-of-extreme-phenotypes-based-on-resilience-to-dementia.pdf
D3.1 4 Proteomic based plasma markers for diagnosis EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.1_4-proteomic-based-plasma-markers-for-diagnosis.pdf
D3.2 4 Proteomic based plasma markers for prognosis EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.2_4-proteomic-based-plasma-markers-for-prognosis.pdf
D3.3 2 Proteomic based CSF markers for prognosis EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3_3_2_proteomic_based_csf_markers_for_prognosis-2.pdf
D3.4 2 Metabolomics based plasma markers for diagnosis EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.4_2-metabolomics-based-plasma-markers-for-diagnosis.pdf
D3.6 4 GWAS-identified SNPs for abnormal CSF abeta and tau and hippocampal atrophy EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.6_4-gwasidentified-snps-for-abnormal-csf-abeta-and-tau-and-hippocampal-atrophy.pdf
D3.8 4 Epigenomic profiles associated with abnormal AD CSF biomarkers EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.8_4-epigenomic-profiles-associated-with-abnormal-ad-csf-biomarkers.pdf
D3.10 Novel combinatorial MRI marker algorithms for diagnosis EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3_10_novel_combinatorial_mri_marker_algorithms_exec_summary_website.pdf
D3.11 2 novel combinatorial MRI marker algorithms for prognosis EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.11_2-novel-combinatorial-mri-marker-algorithms-for-prognosis.pdf
D3.12 Integrative model of biomarkers from different modalities EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.12_integrative-model-of-biomarkers-from-different-modalities.pdf
D3.13 10 Assays of biomarkers for clinical use EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.13_10-assays-of-biomarkers-for-clinical-use.pdf
D3.14 Report joint study AD/Metabolic EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d3.14_report-joint-study-admetabolic.pdf
D4.1 Report on cross-validated plasma, genetic CSF, MRI markers for predementia AD EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d4.1_report-on-crossvalidated-plasma-genetic-csf-mri-markers-for-diagnosis-for-predementia-of-ad.pdf
D4.2 Screening algorithms tested and defined EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d4.2_screening-algorithms-tested-and-defined.pdf
D9.1 Initial requirements and benchmarks set EMIF 28-02-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d9_1_user_requirements_exec_summary_website.pdf
D9.2 Platform requirements v1 and Evaluation Plan EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d9_2_platform_requirements_exec_summary_website.pdf
D9.3 Interim framework evaluation results and requirements v2 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d9_3_interim_framework_evaluation_exec_summary_website.pdf
D9.4 Second framework evaluation results and requirements v3 EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d9_4_second_framework_evaluation_exec_summary_website.pdf
D9.5 Final evaluation results and roadmap for future development EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d9.5_final-evaluation-results-and-roadmap-for-future-development.pdf
D10.1 Initial database fingerprinting EMIF 31-03-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d10_1_initial_fingerprinting_exec_summary_website.pdf
D10.2 First report on federation procedures, ethical and legal issues EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d10_2_federation_procedures_exec_summary_website.pdf
D10.3 Full database fingerprinting EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d10_3_full_fingerprinting_exec_summary_website.pdf
D10.4 First draft of the EMIF Ethical Code of Practice EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d10_4_first_draft_ethical_code_of_practice_exec_summary_website.pdf
D10.5 Final report on federation procedures, legal and ethical issues (including final version of the EMIF Ethical Code of Practice) EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d10.5_-final-version-of-the-emif-code-of-practice.pdf
D11.1 Initial specification of the semantic framework of reference EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d11_1_semantic_framework_initial_exec_summary_website.pdf
D11.2 First version of common data model and associated terminology mapping EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d11_2_first_version_cdm_exec_summary_website.pdf
D11.3 Extended specification of the semantic framework of reference EMIF 30-06-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d11_3_semantic_framework_extended_exec_summary_website.pdf
D11.4 First complete version of the harmonised information model and associated terminology mapping EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d11_4_complete_version_cdm_exec_summary_website.pdf
D11.5 Second version of the harmonised information model and associated terminology mapping EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d11_5_second_version_cdm_exec_summary_website.pdf
D11.6 Final report on harmonisation and semantics EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d11.6_final-report-on-harmonisation-and-semantics.pdf
D12.1 Data extraction software v1 EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12_1_data_extraction_software_v1_exec_summary_website.pdf
D12.2 Data extraction software v2 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12_2_data_extraction_software_v2_exec_summary_website.pdf
D12.3 Interim report on primary data flows, benchmarking and quality analyses EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12_3_benchmarking_data_quality_exec_summary_website.pdf
D12.4 Report on data linkage EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12_4_report_data_linkage_exec_summary_website.pdf
D12.5 Interim report on specialised data extraction, benchmarking, aggregation and processing EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12_5_interim_report_specialised_data_exec_summary_website.pdf
D12.6 Final version of data extraction software EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12.6_final-version-data-extraction-software.pdf
D12.7 Final report on data flows, data integration, processing and linkage EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d12.7_final-report-on-data-flows-data-integration-processing-and-linkage.pdf
D13.1 Evaluation of technologies and tools available for data analysis and visualisation EMIF 30-06-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d13_1_tools_for_data_analysis_and_visualisation_full_webiste.pdf
D13.2 Data analysis tools for vertical projects v1 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d13_2_data_analysis_tools_for_vertical_projects_v1_full_website.pdf
D13.3 Data analysis and visualisation tools, including workflows for linkage with omics data v1 EMIF 30-06-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d13_3_data_analysis_visualisation_tools_v1_full_website.pdf
D13.4 Data analysis tools for vertical projects v2 EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d13_4_data_analysis_tools_for_vertical_projects_v2_full_webiste.pdf
D13.5 Data analysis and visualisation tools, including workflows for linkage with omics data v2 EMIF 31-10-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d13_5_data_analysis_visialisation_tools_v2_full_website.pdf
D13.6 Final suite of modules and tools for data analysis, visualisation and linkage of EHR data with omics data EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d13.6_final-suite-of-modules-and-tools-for-data-analysis.pdf
D14.1 First report on the EMIF-Platform design and architecture including specifications for privacy protection tools and services EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_1_platform_architecture_v1_exec_summary_website.pdf
D14.2 A data management solution for vertical projects, version 1 EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_2_data_mgt_verticals_exec_summary_website.pdf
D14.3 EMIF-Platform, version 1 EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_3_platform_v1_exec_summary_website.pdf
D14.4 System implementation feedback and evaluation report, iteration 1 EMIF 30-04-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_4_system_implementation_feedback_v1_exec_summary_website.pdf
D14.5 A data management solution for vertical projects, version 2 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_5_data_management_verticals_exec_summary_website.pdf
D14.6 EMIF-Platform, version 2 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_6_platform_v2_exec_summary_website.pdf
D14.7 First EMIF-Platform architecture stack EMIF 31-08-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_7_platform_architecture_stack_exec_summary_website.pdf
D14.8 EMIF-Platform, version 3 EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_8_platform_v2_exec_summary_website.pdf
D14.9 System implementation feedback and evaluation report, iteration 3 EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_9_system_implementation_feedback_v3_exec_summary_website.pdf
D14.10 EMIF-Platform, version 4 EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14_10_platform_v4_exec_summary_website.pdf
D14.11 System implementation feedback and evaluation report, iteration 4 EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14.11_system-implementation-feedback-and-evaluation-report-4.pdf
D14.12 Update on EMIF-Platform design, architecture and application guidelines, and Final EMIF-Platform EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d14.12_emif-platform.pdf
D15.1 Report on business models for data exploitation in biosciences EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15_1_business_models_exec_summary_website.pdf
D15.2 Market analysis: usage models and data sources characterisation EMIF 31-08-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15_2_market_analysis_exec_summary_website.pdf
D15.3 Initial business model description EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15_3_initial_business_model_exec_summary_website.pdf
D15.4 First report on outreach activities: leveraging with related initiatives, contacts with external data sources and with key stakeholders EMIF 30-04-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15_4_report_outreach_activities_exec_summary_website.pdf
D15.5 First Draft business plan EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15_5_draft_business_plan_exec_summary_website.pdf
D15.6 Second Draft Business plan EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15_6_second_draft_business_plan_exec_summary_website.pdf
D15.7 Final Business plan EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15.7_final-business-plan.pdf
D15.8 Final report on outreach activities: leveraging with related initiatives, contacts with external data sources and with key stakeholders EMIF 30-06-2018 http://www.emif.eu/wp-content/uploads/2019/01/emif_d15.8_final-report-on-outreach-activities.pdf
D16.1 Operational portal to allow internal team information dissemination, team collaboration, and team document storage. EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_1_operational_portal_exec_summary_website.pdf
D16.2 Templates for dissemination materials: logo design, PPT and poster templates, newsletter formats EMIF 31-03-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_2_templates_dissemination_exec_summary_website.pdf
D16.4 Communication Plan EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_4_communication_plan_exec_summary_website.pdf
D16.5 Project Handbook EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_5_project_handbook_exec_summary_website.pdf
D16.6 Guidance document for EMIF Scientific Publications EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_6_dissemination_process_exec_summary_website.pdf
D16.10 Detailed project and risk plans for WP1‐15 EMIF 30-06-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_10_risk_overview_v1_exec_summary_website.pdf
D16.11 Updated project and risk plans for WP1‐15 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_11_risk_overview_v2_exec_summary_website.pdf
D16.12 Technical and Financial Annual Reports #1 EMIF 31-12-2013 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_12_annual_report_year1_exec_summary_website.pdf
D16.13 Technical and Financial Annual Reports #2 EMIF 31-12-2014 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_13_annual_report_year2_exec_summary_website.pdf
D16.14 Interim Assessment of the Project EMIF 31-08-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_14_interim_assessment_project_exec_summary_website.pdf
D16.15 Technical and Financial Annual Reports #3 EMIF 31-12-2015 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_15_annual_report_year3_exec_summary_website.pdf
D16.16 Technical and Financial Annual Reports #4 EMIF 31-12-2016 http://www.emif.eu/wp-content/uploads/2019/01/emif_d16_16_annual_report_year4_exec_summary_website.pdf
Title First author last name Year Project Link Keywords  
Age dependency of risk factors for cognitive decline Legdeur 2018 EMIF https://doi.org/10.1186/s12877-018-0876-2 Clinical research paper, cognitive decline, risk factors, aging, oldest-old
Capturing the Alzheimer’s disease pathological cascade Tijms 2018 EMIF https://doi.org/10.1016/S1474-4422(18)30043-7 Opinion paper, amyloid, Alzheimer's disease, biomarker, brain imaging, disease progression
Amyloid-β, Tau, and Cognition in Cognitively Normal Older Individuals: Examining the Necessity to Adjust for Biomarker Status in Normative Data Bos 2018 EMIF https://doi.org/10.3389/fnagi.2018.00193 Clinical research paper, amyloid, tau, biomarker, cognition, dementia, ADNI
Inter-laboratory Proficiency Processing scheme in CSF aliquoting: Implementation and assessment based on biomarkers of Alzheimer’s Disease Lewczuk 2018 EMIF http://dx.doi.org/10.1186/s13195-018-0418-3 Clinical research paper, CSF, biomarker, tau, Amyloid, Alzheimer's disease, training
The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics Bos 2018 EMIF https://doi.org/10.1186/s13195-018-0396-5 Clinical research paper, study protocol, study design, biomarker, cognitive, ApoE, dementia, Alzheimer's disease
MRI predictors of amyloid pathology: results from the EMIF-AD multimodal biomarker discovery study Ten Kate 2018 EMIF https://doi.org/10.1186/s13195-018-0428-1 Clinical research paper, MRI, amyloid, mild cognitive impairment, ApoE, brain imaging
CSF non-phosphorylated Tau as a biomarker for the discrimination of AD from CJD Ermann 2018 EMIF https://doi.org/10.1002/acn3.584 Clinical research paper, biomarker, CSF, Tau, Alzheimer's disease, Creuzfeld-Jacob disease
Diagnostic value of cerebrospinal fluid tau, neurofilament, and progranulin in definite frontotemporal lobar degeneration Goossens 2018 EMIF https://doi.org/10.1186/s13195-018-0364-0 Clinical research paper, biomarkers, tau, amyloid, CSF, Alzheimer's disease, frontotemporal lobar degeneration
White paper by the Society for CSF Analysis and Clinical Neurochemistry: Overcoming barriers in biomarker development and clinical translation Teunissen 2018 EMIF https://doi.org/10.1186/s13195-018-0359-x White paper, CSF, biomarker, neurological disease, Alzheimer's disease
Neurogranin as Cerebrospinal Fluid Biomarker for Alzheimer Disease: An Assay Comparison Study Willemse 2018 EMIF https://doi.org/10.1373/clinchem.2017.283028 Clinical research paper, biomarker, CSF, dementia, frontotemporal dementia, Alzheimer's disease, Dementia with lewy bodies, vascular dementia, diagnosis
Added Diagnostic Value of Cerebrospinal Fluid Biomarkers for Differential Dementia Diagnosis in an Autopsy-Confirmed Cohort Niemantsverdriet 2018 EMIF https://doi.org/10.3233/JAD-170927 Clinical research paper, CSF, biomarker, dementia, diagnosis, cohort
Long Non-Coding RNAs Associated with Metabolic Traits in Human White Adipose Tissue. Gao 2018 EMIF https://doi.org/10.1016/j.ebiom.2018.03.010 Basic science research paper, clinical research, lncRNA, adipocyte, metabolism, RNA-seq
Gray matter network disruptions and amyloid beta in cognitively normal adults Ten Kate 2018 EMIF https://doi.org/10.3389/fnagi.2018.00067 Clinical research paper, amyloid, PET, MRI, Alzheimer's disease
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer's disease Lewczuk 2018 EMIF https://doi.org/10.1186/s13195-018-0404-9 Clinical research paper, biomarker, amyloid, tau, Alzheimer's disease
Amyloid β oligomers (AβOs) in Alzheimer's disease Mroczko 2018 EMIF https://doi.org/10.1007/s00702-017-1820-x Review article, biomarkers, amyloid, CSF, Alzheimer's disease
A Specific Reduction in Aβ1-42 vs. a Universal Loss of Aβ Peptides in CSF Differentiates Alzheimer's Disease from Meningitis and Multiple Sclerosis. Spitzer 2018 EMIF https://doi.org/10.3389/fnagi.2018.00152 Clinical research paper, biomarker, CSF, amyloid, Alzheimer's disease, meningitis, multiple sclerosis, diagnosis
White matter hyperintensities and vascular risk factors in monozygotic twins Ten Kate 2018 EMIF https://doi.org/10.1016/j.neurobiolaging.2018.02.002 Clinical research paper, MRI, brain imaging, risk factor, vascular
Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia Jansen 2018 EMIF https://doi.org/10.1001/jamapsychiatry.2017.3391 Clinical research paper, amyloid, cognition, mild cognitive impairment, MMSE, dementia
Screening of Potential Adipokines Identifies S100A4 as a Marker of Pernicious Adipose Tissue and Insulin Resistance Arner 2018 EMIF https://doi.org/10.1038/s41366-018-0018-0 Clinical research paper, adipokine, adipose tissue, obesity, diabetes
Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation Lewczuk 2018 EMIF https://doi.org/10.1080/15622975.2017.1375556 Consensus paper, biomarker, Alzheimer's disease, dementia, CSF, review
Dementia prevalence and incidence in a federation of European Electronic Health Record databases: The European Medical Informatics Framework resource Perera 2018 EMIF https://doi.org/10.1016/j.jalz.2017.06.2270 Clinical research paper, Dementia, Incidence, Prevalence, Electronic Health Records, European Medical Informatics Framework
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer's Disease Mroczko 2018 EMIF https://doi.org/10.3390/ijms19071884 Review article, amyloid beta oligomer, protein aggregation, AβO receptors, Alzheimer’s disease, neurodegeneration
The EMIF-AD PreclinAD study: study design and baseline cohort overview Konijnenberg 2018 EMIF https://doi.org/10.1186/s13195-018-0406-7 Clinical research paper, clinical study protocol, Preclinical Alzheimer’s disease, Amyloid, Cognitively normal, Monozygotic twins, [18F]flutemetamol
Key Ethical Challenges in the European Medical Information Framework Floridi 2018 EMIF https://doi.org/10.1007/s11023-018-9467-4 Medical ethics paper, data ethics, ethics of algorithms, health ethics, GDPR
MONTRA: An agile architecture for data publishing and discovery Silva 2018 EMIF https://doi.org/10.1016/j.cmpb.2018.03.024 Informatics research paper, biomedical databases, data catalogues, patient registries, clinical studies
A methodology for fine-grained access control in exposing biomedical data Trifan 2018 EMIF https://doi.org/10.3233/978-1-61499-852-5-561 Methodology paper, bioinformatics, data access, data sharing
Real world data reveal a diagnostic gap in non-alcoholic fatty liver disease Alexander 2018 EMIF https://doi.org/10.1186/s12916-018-1103-x Clinical research paper, epidemiology, real world data, electronic health records, population, NAFLD, NASH
A modular workflow management framework Almeida 2018 EMIF http://doi.org/10.5220/0006583104140421 Conference proceedings, informatics, task Management, workflow Management, clinical studies.
A methodology to perform semi-automatic distributed EHR database queries Fajarda 2018 EMIF http://doi.org/10.5220/0006579701270134 Methodology paper, electronic health records, observational studies, cohorts, clinical research, secondary use of data
A De-Identification Pipeline for Ultrasound Medical Images in DICOM Format. Monteiro 2018 EMIF https://doi.org/10.1007/s10916-017-0736-1 Informatics research paper, medical imaging, OCR, neural networks, deep-learning, de-identification
comoRbidity: An R package for the systematic analysis of disease comorbidities. Gutiérrez-Sacristán 2018 EMIF https://doi.org/10.1093/bioinformatics/bty315 Informatics research paper, electronic health records, R, software, comorbidity
Identifying temporal patterns in patient disease trajectories using dynamic time warping: A population-based study Giannoula 2018 EMIF https://doi.org/10.1038/s41598-018-22578-1 Informatics research paper, clinical research paper, electronic health records, comorbidity, bioinformatics, disease prediction
The frequency and influence of dementia risk factors in prodromal Alzheimer's disease Bos 2017 EMIF https://doi.org/10.1016/j.neurobiolaging.2017.03.034 Clinical research paper, Alzheimer's disease, Risk factors, IWG-2 criteria, NIA-AA criteria, Biomarkers, Prognosis
Does genetic risk help to predict amyloid burden in a non-demented population? A Bayesian approach Voyle 2017 EMIF https://doi.org/10.1101/174995 Clinical research paper, informatics, amyloid, risk factor, CSF, ApoE, ADNI
Strategic roadmap for an early diagnosis of Alzheimer’s disease based on biomarkers Frisoni 2017 EMIF https://doi.org/10.1016/S1474-4422(17)30159-X Opinion paper, biomarkers, Alzheimer's disease, diagnostics, brain imaging
Amyloid-independent atrophy patterns predict time to progression to dementia in MCI Ten Kate 2017 EMIF https://doi.org/10.1186/s13195-017-0299-x Clinical research paper, MRI, amyloid, brain imaging, mild cognitive impairment, dementia, CSF
Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline Bos 2017 EMIF https://doi.org/10.1186/s13195-017-0328-9 Clinical research paper, MRI, amyloid, cognitive decline, cerebrovascular dysfunction
Clinical validity of medial temporal atrophy as a biomarker for Alzheimer’s disease in the context of a structured 5-phase development framework Ten Kate 2017 EMIF https://doi.org/10.1016/j.neurobiolaging.2016.05.024 Review article, recommendations, clinical research, biomarker, MRI, Alzheimer's disease
Cognitive functioning of individuals aged 90 years and older withoutdementia: A systematic review Legdeur 2017 EMIF https://doi.org/10.1016/j.arr.2017.02.006 Systematic review, dementia, cognition, aging, MMSE scores
Brain Amyloid Pathology and Cognitive Function - Alzheimer Disease Without Dementia? Visser 2017 EMIF https://doi.org/10.1001/jama.2017.6895 Editorial, biomarker, amyloid, Alzheimer's disease, dementia, MRI, brain imaging
Association of blood lipids with Alzheimer’s Disease: a comprehensive lipidomics analysis Proitsi 2017 EMIF https://doi.org/10.1016/j.jalz.2016.08.003 Clinical research paper, Alzheimer's disease, Dementia, Brain atrophy, sMRI, Rate of cognitive decline, Lipidomics, Metabolomics, Biomarkers, Machine learning, Multivariate, Classification
Real world big data for clinical research and drug development Singh 2017 EMIF https://doi.org/10.1016/j.drudis.2017.12.002 Review article, informatics, big data, real world data, electronic health records, drug development
General guidelines for biomedical software development Silva 2017 EMIF https://doi.org/10.12688/f1000research.10750.2 Guidelines, informatics, biomedical software, software development, bioinformatics, Agile,
Data Integration and Sharing Supporting Drug R&D Sanz 2017 EMIF https://doi.org/10.1016/B978-0-12-409547-2.12297-8 Review article, Biana, Big data, ChEMBL, ClinicalTrials.gov, Data integration, Data management, Databases, DisGeNET, diXa, Drug Bank, DSSTox, EMIF, eTOX, EU-ADR, EudraCT, EudraPharm, HIPPIE, Human Interactome database, Open PHACTS, Reactome, STRING, SureChEMBL, Text-mining, Tox21, ToxCast
The European Institute for Innovation through Health Data Kalra 2016 EMIF http://dx.doi.org/10.1002/lrh2.10008 Commentary, electronic health records, health data, data sharing, clinical research, big data
Using Electronic Health Records to Assess Depression and Cancer Comorbidities Mayer 2017 EMIF https://doi.org/10.3233/978-1-61499-753-5-236 Clinical research paper, informatics, electronic health records, depression, cancer, comorbidities
Nine Principles of Semantic Harmonization Cunningham 2017 EMIF https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333211/ Recommendations, informatics, clinical cohort data, data harmonisation, EMIF Knowledge Object Library
Mitochondrial genes are altered in blood early in Alzheimer's disease Lunnon 2017 EMIF https://doi.org/10.1016/j.neurobiolaging.2016.12.029 Clinical research paper, Mitochondria, Alzheimer's disease, Gene expression, Blood, Biomarker, Mild cognitive impairment, Oxidative phosphorylation
Functional and effective whole brain connectivity using magnetoencephalography to identify monozygotic twin pairs Demuru 2017 EMIF https://doi.org/10.1038/s41598-017-10235-y Clinical research paper, PreclinAD, EEG, Neurophysiology, Neuroscience
Cerebrospinal Fluid Aβ42/40 Corresponds Better than Aβ42 to Amyloid PET in Alzheimer's Disease Lewczuk 2016 EMIF http://dx.doi.org/10.3233/JAD-160722 Clinical research paper, Alzheimer’s disease, amyloid-β, biomarker, cerebrospinal fluid, positron emission tomography
Complement Biomarkers as predictors of disease progression in Alzheimer’s disease Hakobyan 2016 EMIF https://dx.doi.org/10.3233/JAD-160420 Clinical research paper, Alzheimer’s disease, MCI, biomarker, complement, inflammation, plasma
Identificare i casi di diabete tipo 2 in una rete di fonti di dati eterogenee la strategia del progetto EMIF Roberto 2016 EMIF https://www.ars.toscana.it/files/progetti/informatica_medica/BEN_diabete2_EMIF.pdf Clinical research paper, electronic health records, diabetes, algorithms
Non-Phosphorylated Tau as a Potential Biomarker of Alzheimer’s Disease: Analytical and Diagnostic Characterization Lewczuk 2016 EMIF https://dx.doi.org/10.3233/JAD-160448 Clinical research paper, biomarkers, cerebrospinal fluid, phosphorylation, tau
Genetic risk and plasma tau as markers of amyloid-beta and tau burden in cerebrospinal fluid Voyle 2016 EMIF https://dx.doi.org/10.3233/JAD-160707 Clinical research paper, Alzheimer’s disease, biomarker, blood, multi-modal, polygenic risk score, tau
Identifying Cases of Type 2 Diabetes in Heterogeneous Data Sources: Strategy from the EMIF Project Roberto 2016 EMIF https://dx.doi.org/10.1371/journal.pone.0160648 Clinical research paper, diabetes, diagnosis, algorithms, harmonisation
Data Safe Havens and Trust: Toward a Common Understanding of Trusted Research Platforms for Governing Secure and Ethical Health Research Lea 2016 EMIF https://dx.doi.org/10.2196/medinform.5571 Opinion paper, clinical research support, data safe havens, genomics research support, health record linkage supported research, legislative and regulatory compliance, public engagement, public involvement, trusted research platforms, trusted researchers
Genetic variations underlying Alzheimer's disease: evidence from genome-wide association studies and beyond Cuyvers 2016 EMIF https://dx.doi.org/10.1016/S1474-4422(16)00127-7 Review article, Alzheimer's disease, ApoE, TREM2, risk, GWAS
A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium Somers 2016 EMIF https://dx.doi.org/10.3233/JAD-151097 Clinical research paper, Alzheimer’s disease, amyloid, biomarkers, cerebrospinal fluid, dementia, diagnosis, mild cognitive impairment, neuropathology, tau
Validation of microRNAs in Cerebrospinal Fluid as Biomarkers for Different Forms of Dementia in a Multicenter Study Müller 2016 EMIF https://dx.doi.org/10.3233/JAD-160038 Clinical research paper, Alzheimer’s disease, Lewy body disease, cerebrospinal fluid, frontotemporal dementia, microRNAs, mild cognitive impairment
sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. Suárez-Calvet 2016 EMIF https://dx.doi.org/10.15252/emmm.201506123 Clinical research paper, CSF, Alzheimer's disease, TREM2, biomarkers, microglia, neurodegeneration
Gray matter network disruptions and amyloid beta in cognitively normal adults Tijms 2016 EMIF https://dx.doi.org/10.1016/j.neurobiolaging.2015.10.015 Clinical research paper, Alzheimer's disease, Amyloid beta, Cognitively normal adults, Graph theory, Gray matter, MRI, Single-subject
Diagnostic Impact of Cerebrospinal Fluid Biomarker (Pre-)Analytical Variability in Alzheimer's Disease Niemantsverdriet 2016 EMIF https://dx.doi.org/10.3233/JAD-150953 Clinical research paper, Alzheimer’s disease, MCI, biomarkers, cerebrospinal fluid, diagnostic accuracy, differential dementia diagnosis
Impact of APOE-e4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults Ten Kate 2016 EMIF https://dx.doi.org/10.1016/j.neurobiolaging.2015.10.018 Clinical research paper, Alzheimer's disease, Apolipoprotein E, Dementia, Family history, MRI, Voxel-based morphometry
Semantic Knowledge Base Construction from Radiology Reports Monteiro 2016 EMIF https://dx.doi.org/10.5220/0005709503450352 Informatics research paper, Semantic Web, Healthcare Information Management, Clinical Reports, Radiology, Text-mining.
Comparison of Different Matrices as Potential Quality Control Samples for Neurochemical Dementia Diagnostics Lelental 2016 EMIF https://www.ncbi.nlm.nih.gov/pubmed/26967210 Clinical research paper, Alzheimer’s disease, amyloid-β, biomarkers, cerebrospinal fluid, laboratory diagnostics, quality control, tau
PsyGeNET: a knowledge platform on psychiatric disorders and their genes Gutiérrez-Sacristán 2015 EMIF https://dx.doi.org/10.1093/bioinformatics/btv301 Informatics research paper, risk factors, platform, database text mining, depression, addiction
Alzheimer's disease - Recent biomarker developments in relation to updated diagnostic criteria Höglund 2015 EMIF https://dx.doi.org/10.1016/j.cca.2015.01.041 Review article, Alzheimer's disease, Biomarker, Cerebrospinal fluid, Diagnosis, Tau, β-Amyloid
Validation of the Erlangen Score Algorithm for the prediction of the development of dementia due to AD in pre-dementia subjects Lewczuk 2015 EMIF https://dx.doi.org/10.3233/JAD-150342 Clinical research paper, Alzheimer’s disease, ADNI, diagnosis, biomarkers, cerebrospinal fluid, clinical neurochemistry, results interpretation, validation
Age-stratified prevalence of mild cognitive impairment and dementia in European populations, a systematic review Alexander 2015 EMIF https://dx.doi.org/10.3233/JAD-150168 Clinical research paper, short communication, meta-analysis, Dementia, epidemiology, mild cognitive impairment, prevalence
A novel multi-tissue diagnostic of healthy ageing can determine cognitive health status using blood RNA Sood 2015 EMIF https://dx.doi.org/10.1186/s13059-015-0750-x Clinical research paper, Alzheimer's disease, genetic profiling, biomarker
Boosting translational research on Alzheimer's disease in Europe: The Innovative Medicine Initiative AD research platform Vaudano 2015 EMIF https://dx.doi.org/10.1016/j.jalz.2015.02.002 Review article, opinion paper, Alzheimer's disease, IMI, incidence
No evidence to suggest that the use of acetylcholinesterase inhibitors confounds the results of two blood-based biomarker studies in Alzheimer’s disease Chiam 2015 EMIF https://dx.doi.org/10.3233/JAD-150289 Clinical research paper, Alzheimer’s disease, blood, cholinesterase inhibitors, gene expression, microarray, protein, proteomics
Biomarkers for Alzheimer's disease: a controversial topic Frisoni 2015 EMIF https://dx.doi.org/10.1016/S1474-4422(15)00150-7 Commentary, Alzheimer's disease, biomarker, CSF, Tau, Amyloid, PET
Generalizability of the disease state index prediction model for identifying patients progressing from mild cognitive impairment to Alzheimer's disease. Hall 2015 EMIF https://dx.doi.org/10.3233/JAD-140942 Clinical research paper, Alzheimer's disease, computer-assisted diagnosis, dementia, magnetic resonance imaging (MRI), mild cognitive impairment
Blood protein markers of Neocortical Amyloid Burden: A candidate study using SOMAscan technology Voyle 2015 EMIF https://dx.doi.org/10.3233/JAD-150020 Clinical research paper, Alzheimer’s disease, amyloid plaques, blood, positron emission tomography scan, proteomics, biomarker
Cerebrospinal fluid P-tau181P: biomarker for improved differential diagnosis Struyfs 2015 EMIF https://dx.doi.org/10.3389/fneur.2015.00138 Clinical research paper, Alzheimer’s disease, biomarkers, cerebrospinal fluid, dementia, differential diagnosis, neuropathology, tau
Plasma protein biomarkers of Alzheimer’s disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes Kiddle 2015 EMIF https://dx.doi.org/10.1038/tp.2015.78 Clinical research paper, Alzheimer's disease, blood, biomarker, proteomics, MAPK
Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis Jansen 2015 EMIF https://dx.doi.org/10.1001/jama.2015.4668 Clinical research paper, meta-analysis, Longitudinal, Observational, Biomarkers, Cognitive markers, Alzheimer's disease, Asymptomatic, MCI, Dementia
Importance and impact of pre-analytical variables on Alzheimer’s disease biomarker levels in cerebrospinal fluid Le Bastard 2015 EMIF https://dx.doi.org/10.1373/clinchem.2014.236679 Clinical research paper, Alzheimer's disease, biomarker, CSF, amyloid, tau
Prevalence and prognosis of Alzheimer’s disease at the mild cognitive impairment stage Vos 2015 EMIF https://dx.doi.org/10.1093/brain/awv029 Clinical research paper, Alzheimer’s disease, MCI, biomarkers, diagnostic criteria, IWG-1, IWG-2, prognosis
Linking genetics of brain changes to Alzheimer’s disease: sparse whole genome association scan of regional MRI volumes in the ADNI and AddNeuroMed cohorts Khondoker 2015 EMIF https://dx.doi.org/10.3233/JAD-142214 Clinical research paper, Alzheimer's disease, GWAS, imaging quantitative trait loci, magnetic resonance imaging, mild cognitive impairment
An Integrated Workflow for Multiplex CSF Proteomics and Peptidomics-Identification of Candidate Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Hölttä 2015 EMIF https://dx.doi.org/10.1021/pr501076j Clinical research paper, Alzheimer’s disease, biomarker discovery, cerebrospinal fluid, clinical proteomics, mass spectrometry, neurodegenerative disease, peptidomics, quantification
TDP-43 as a possible biomarker for frontotemporal lobar degeneration: a systematic review of existing antibodies Goossens 2015 EMIF https://dx.doi.org/10.1186/s40478-015-0195-1 Systematic review, TDP-43, Antibodies, Immunoassay, Biomarkers, Frontotemporal lobar degeneration (FTLD)
Overdiagnosing vascular dementia using structural brain imaging for dementia work-up Niemantsverdriet 2015 EMIF https://dx.doi.org/10.3233/JAD-142103 Clinical research paper, short communication, Alzheimer's disease, brain imaging, dementia, differential dementia diagnosis, MRI, vascular dementia
Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer’s disease Proitsi 2015 EMIF https://dx.doi.org/10.1038/tp.2014.127 Clinical research paper, Alzheimer's disease, MCI, metabolomics, plasma, cholesterol, diagnosis
Diagnostic accuracy of CSF amyloid-β isoforms for early and differential dementia diagnosis Struyfs 2015 EMIF https://dx.doi.org/10.3233/JAD-141986 Clinical research paper, Alzheimer's disease, MCI, amyloid, biological markers, cerebrospinal fluid, diagnosis
Reuse of EHRs to Support Clinical Research in a Hospital of Reference Mayer 2015 EMIF https://dx.doi.org/10.3233/978-1-61499-512-8-224 Informatics research paper, clinical research, electronic health records, database, diabetes, dementia, platform
Blood protein predictors of brain amyloid for enrichment in clinical trials? Ashton 2015 EMIF https://doi.org/10.1016/j.dadm.2014.11.005 Clinical research paper, Alzheimer's disease, Plasma, β amyloid, Proteomics, Biomarker, Fibrinogen γ-chain, ageing
Longitudinal protein changes in blood plasma associated with the rate of cognitive decline in Alzheimer's disease Sattlecker 2015 EMIF https://dx.doi.org/10.3233/JAD-140669 Clinical research paper, Alzheimer’s disease, MCI, cognitive decline, complement cascade, cytokine-cytokine receptor interaction, plasma, proteomics
Alzheimer's disease: a report from the 7th Kuopio Alzheimer symposium Haapasalo 2015 EMIF https://doi.org/10.2217/nmt.15.31 Conference report, Alzheimer's disease, biomarkers, brain imaging, diagnosis, prediction, prevention, randomized controlled trial
A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis Voyle 2015 EMIF https://dx.doi.org/10.3233/JAD-150440 Clinical research paper, Alzheimer’s disease, blood, gene expression, microarray, pathways
Challenges and opportunities for exploring patient-level data Lopes 2015 EMIF https://dx.doi.org/10.1155/2015/150435 Review article, personalised medicine, clinical data, genomics, diagnosis
The genetic landscape of Alzheimer's disease: clinical implications and perspectives Van Cauwenberghe 2015 EMIF https://dx.doi.org/10.1038/gim.2015.117 Review article, Alzheimer's disease, genetics, ApoE, risk factor, diagnosis, GWAS
Current developments in dementia risk prediction modelling: An updated systematic review Tang 2015 EMIF https://dx.doi.org/10.1371/journal.pone.0136181 Systematic review, Alzheimer's disease, clinical, dementia, risk, patient
Café Variome: General-Purpose Software for Making Genotype-Phenotype Data Discoverable in Restricted or Open Access Contexts Lancaster 2015 EMIF https://dx.doi.org/10.1002/humu.22841 Informatics research paper, Cafe Variome, Matchmaker Exchange, data discovery, genotype-phenotype, data sharing, software
Architecture to summarize patient-level data across borders and countries Bastião Silva 2015 EMIF https://dx.doi.org/10.3233/978-1-61499-564-7-687 Informatics research paper, clinical data, healthcare, database, aggregation
Blood metabolite markers of neocortical amyloid-β burden: Discovery and enrichment using candidate proteins Voyle 2015 EMIF https://dx.doi.org/10.1038/tp.2015.205 Clinical research paper, Alzheimer's disease, metabolomics, proteomics, PET, ADNI
C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease De Vos 2015 EMIF https://dx.doi.org/10.1016/j.jalz.2015.05.012 Clinical research paper, Alzheimer's disease, Amyloid, CSF biomarker, ELISA, Mild cognitive impairment, Neurogranin, Plasma biomarker, Prognostic biomarker, Ratio amyloid β, tau, γ-secretase
Prevalence of Amyloid PET Positivity in Dementia Syndromes: A Meta-Analysis Ossenkoppele 2015 EMIF https://jamanetwork.com/journals/jama/fullarticle/2293296 Clinical research paper, meta-analysis, Alzheimer's disease, dementia, diagnostic criteria, ApoE, PET, Amyloid
Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects Toledo 2015 EMIF https://dx.doi.org/10.1093/brain/awv199 Clinical research paper, Alzheimer’s disease, biomarkers, CSF, cognitive ageing, dementia, imaging
Diffusion kurtosis imaging: a biomarker for early diagnosis of Alzheimer’s disease? Struyfs 2015 EMIF https://dx.doi.org/10.3233/JAD-150253 Clinical research paper, Alzheimer’s disease, biomarker, diffusion kurtosis imaging, diffusion tensor imaging, early diagnosis, MRI, MCI
A 22-SNP Alzheimer risk score correlates with family history, onset age and CSF Aβ42 Sleegers 2014 EMIF https://dx.doi.org/10.1016/j.jalz.2015.02.013 Clinical research paper, Alzheimer's disease, Genetic risk profile, Genotype-phenotype correlation, CSF Aβ1–42, Onset age, Family history
Diagnostic value of MIBG cardiac scintigraphy for differential dementia diagnosis Slaets 2014 EMIF https://dx.doi.org/10.1002/gps.4229 Clinical research paper, Alzheimer's disease, MIBG cardiac scintigraphy, dementia, dementia with Lewy bodies, sensitivity, specificity
Temporal evolution of biomarkers and cognitive markers in the asymptomatic, MCI, and dementia stage of Alzheimer's disease Bertens 2014 EMIF https://dx.doi.org/10.1016/j.jalz.2014.05.1754 Clinical research paper, Alzheimer's disease, dementia, MCI, biomarker, amyloid
Circulating Proteomic Signatures of Chronological Age Menni 2014 EMIF https://dx.doi.org/10.1093/gerona/glu121 Clinical research paper, aging, aptamers, blood biomarkers, early development, gene expression, proteomics
Depression in mild cognitive impairment is associated with progression to Alzheimer's disease: a longitudinal study Van der Mussele 2014 EMIF https://dx.doi.org/10.3233/JAD-140405 Clinical research paper, Alzheimer's disease, BPSD, cox proportional hazard, association, dementia, depression, depressive symptoms, MCI, predictor, prognostic value
Plasma proteins predict conversion to dementia from prodromal disease Hye 2014 EMIF https://dx.doi.org/10.1016/j.jalz.2014.05.1749 Clinical research paper, Alzheimer's disease, biomarker, MCI, pathology, plasma, prediction and MRI
Egas: a collaborative and interactive document curation platform Campos 2014 EMIF https://dx.doi.org/10.1093/database/bau048 Informatics research paper, platform, text mining, curation, database, biomedical
Validation of the AD-CSF-index in autopsy-confirmed Alzheimer's disease patients and healthy controls Struyfs 2014 EMIF https://dx.doi.org/10.3233/JAD-131085 Clinical research paper, Alzheimer's disease, biomarkers, cerebrospinal fluid, diagnostic accuracy, sensitivity, specificity
Advanced glycation end products, dementia and diabetes Lovestone 2014 EMIF https://dx.doi.org/10.1073/pnas.1402277111 Editorial, Alzheimer's disease, dementia, diabetes, sirtuin, ageing
Medical imaging archiving: a comparison between several NoSQL solutions LAB Silva 2014 EMIF https://doi.org/10.1109/BHI.2014.6864305 Informatics research paper, Platform, DICOM , Picture archiving and communication systems , File systems , Indexing
Normalizing medical imaging archives for dose quality assurance and productivity auditing LAB Silva 2014 EMIF https://dx.doi.org/10.1007/s10278-015-9805-5 Informatics research paper, Medical imaging, PACS, ALARA, DICOM, monitoring, quality of service, radiation
Semantic search over DICOM repositories LAB Silva 2014 EMIF https://doi.org/10.1109/ICHI.2014.41 Informatics research paper, Platform, Ontologies , DICOM , Standards , Semantics , Picture archiving and communication systems , Medical services
Unresolved questions in Alzheimer's research - will biomarkers help? Zetterberg 2013 EMIF https://dx.doi.org/10.2217/bmm.13.120 Opinion, Alzheimer's disease, amyloid, biomarkers, disease-modifying therapy, pathogenesis, tau
Preclinical Alzheimer’s disease and its outcome: a longitudinal cohort study Vos 2013 EMIF http://dx.doi.org/10.1016/S1474-4422(13)70194-7 Clinical research paper, Alzheimer's disease, CSF, progression, outcome, longitudinal cohort study
Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60–102 Years Legdeur 2019 EMIF https://doi.org/10.1093/gerona/glz180 Clinical research paper, Alzheimer's disease, Biomarkers, Brain aging, Cognitive function, Human aging
TASKA: A modular task management system to support health research studies Almeida 2019 EMIF https://doi.org/10.1186/s12911-019-0844-6 Informatics research paper, Clinical studies, Task management, Workflow management
White Matter Hyperintensities and Hippocampal Atrophy in Relation to Cognition: The 90+ Study Legdeur 2019 EMIF https://doi.org/10.1111/jgs.15990 Clinical research study, cognitive functioning, hippocampal atrophy, oldest-old, white matter hyperintensities
The association of vascular disorders with incident dementia in different age groups Legdeur 2019 EMIF https://doi.org/10.1186/s13195-019-0496-x Clinical research paper, Dementia, Primary care, Vascular disorders, Vascular disease, Cardiovascular risk factors, Aging
Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the EMIF-AD biomarker discovery cohort Kim 2019 EMIF https://doi.org/10.1016/j.jalz.2019.03.004 Clinical research paper, Alzheimer's disease, Amyloid, Biomarkers, Brain volume measurements, CSF, Cognitive function measurements, Dementia, EMIF-AD, Metabolomics, Tau
Inflammatory biomarkers in Alzheimer's disease plasma Morgan 2019 EMIF https://doi.org/10.1016/j.jalz.2019.03.007 Clinical research paper, Alzheimer's disease, Biomarker, Plasma, Inflammation, Complement
EMIF Catalogue: A collaborative platform for sharing and reusing biomedical data Oliveira 2019 EMIF https://doi.org/10.1016/j.ijmedinf.2019.02.006 Informatics research paper, Biomedical data integration, Data catalogue, Data discovery, Data reuse, Data sharing, Research study
Advantages and disadvantages of the use of the CSF Amyloid β (Aβ) 42/40 ratio in the diagnosis of Alzheimer’s Disease Hansson 2019 EMIF https://doi.org/10.1186/s13195-019-0485-0 Review article, Alzheimer’s Disease, Amyloidβ Peptides, Aβ42/40 ratio, Biomarkers, Cerebrospinal Fluid
Searching for novel cerebrospinal fluid biomarkers of tau pathology in frontotemporal dementia: an elusive quest Foiani 2019 EMIF https://doi.org/10.1136/jnnp-2018-319266 Clinical research paper, frontotemporal dementia, CSF, tau
Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum Bos 2019 EMIF https://doi.org/10.1016/j.jalz.2019.01.004 Clinical research paper, APOE, Alzheimer's disease, Amyloid-β, Cerebrospinal fluid, Cognition, Neurofilament light, Neurogranin, YKL-40
Plasma Protein Biomarkers for the Prediction of CSF Amyloid and Tau and [18F]-Flutemetamol PET Scan Result Westwood 2018 EMIF https://doi.org/10.3389/fnagi.2018.00409 Clinical research paper, Alzheimer’s disease, amyloid, tau, biomarkers, proteomics, plasma, blood, ficolin-2
Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease Baldeiras 2018 EMIF https://doi.org/10.1186/s13195-018-0456-x Clinical research paper, Alzheimer’s disease, Biomarker, Cerebrospinal fluid, MCI, progression
Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study Legdeur 2018 EMIF https://doi.org/10.1186/s12877-018-0984-z Clinical study protocol, Alzheimer’s disease, Amnestic mild cognitive impairment, Amyloid, Cognitive impairment, Dementia, Magnetoencephalography (MEG), Oldest-old, Positron emission tomography, Resilience
Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions ven de Kreeke 2018 EMIF https://doi.org/10.1167/iovs.18-25341 Clinical research study, small vessel disease, retina, vascular, MRI, twins
The European Medical Information Framework: A Novel Ecosystem for Sharing Healthcare Data Across Europe Lovestone 2019 EMIF https://doi.org/10.1002/lrh2.10214 Review article, EMIF, EMIF‐AD, EMIF‐MET, catalogue, use case, Alzheimer's disease
Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort Westwood 2020 EMIF https://pubmed.ncbi.nlm.nih.gov/31985466/ Clinical research paper, Alzheimer’s disease, amyloid-β, biomarkers, plasma, proteomics.
A Metabolite-Based Machine Learning Approach to Diagnose Alzheimer-type Dementia in Blood: Results From the EMIF-AD Biomarker Discovery Cohort Stamate 2019 EMIF https://doi.org/10.1016/j.trci.2019.11.001 Clinical research paper, Alzheimer's disease, Biomarkers, EMIF-AD, Machine-Learning, Metabolomics.
Associations of Brain Pathology, Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60-102 Years Legdeur 2019 EMIF https://pubmed.ncbi.nlm.nih.gov/31411322/ Clinical research paper, biomarkers, brain aging, cognitive function, human aging.
APOE ε4 Genotype-Dependent Cerebrospinal Fluid Proteomic Signatures in Alzheimer's Disease Konijnenberg 2020 EMIF https://doi.org/10.1186/s13195-020-00628-z Clinical research paper, Alzheimer's disease, APOE genotype, Amyloid aggregation, CSF proteomics.
Ocular Biomarkers for Cognitive Impairment in Nonagenarians; A Prospective Cross-Sectional Study van der Kreeke 2020 EMIF https://doi.org/10.1186/s12877-020-01556-1 Clinical research paper, Cognitive impairment, Fundus photography, Nonagenarians;,Ocular biomarkers, Optical coherence tomography, Retina, Alzheimer's disease
Biomarker-based Prognosis for People With Mild Cognitive Impairment (ABIDE): A Modelling Study van Maurik 2019 EMIF https://doi.org/10.1016/S1474-4422(19)30283-2 Clinical research paper, MCI, biomarker, risk, dementia, Alzheimer's disease, CSF
Longitudinal retinal layer changes in preclinical Alzheimer's disease van de Kreeke 2020 EMIF https://doi.org/10.1111/aos.14640 OCT, ocular biomarkers, preclinical Alzheimer’s disease, retina, twins
Methotrexate and relative risk of dementia amongst patients with rheumatoid arthritis: a multi-national multi-database casecontrol study Newby 2020 EMIF https://doi.org/10.1186/s13195-020-00606-5 Dementia, Rheumatoid arthritis, Inflammation, Anti-inflammatory drugs, DMARDs, Methotrexate, Sulfasalazine, Case-control study, European Medical Information Framework, EMIF
Pathophysiological subtypes of Alzheimer’s disease based on cerebrospinal fluid proteomics Tijms 2020 EMIF https://doi.org/10.1093/brain/awaa325 Alzheimer’s disease, cerebrospinal fluid, proteomics, subtypes, amyloid, tau, proteins, cerebrospinal fluid, genetics
Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset Hong 2020 EMIF https://doi.org/10.1038/s41398-020-01074-z Genome-wide association study, Alzheimer's disease , CSF biomarkers , Multimodal Biomarker Discovery dataset,
What determines cognitive functioning in the oldest-old? The EMIF-AD 90+ Stud Legdeur 2020 EMIF https://doi.org/10.1093/geronb/gbaa152 Alzheimer’s disease, brain pathology biomarkers, cognitive aging, oldest-old, risk factors.
Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer’s Disease Pathology Shi 2020 EMIF https://doi.org/10.3233/jad-200208 ATN framework, Dickkopf-1, SomaScan, Wnt signaling, replication.
Treatment pathway analysis of newly diagnosed dementia patients in four electronic health record databases in Europe James 2020 EMIF https://doi.org/10.1007/s00127-020-01872-2 Alzheimer’s disease, Dementia, Epidemiology, Real-world data.
Amyloid-β, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old Pelkmans 2021 EMIF https://onlinelibrary.wiley.com/doi/full/10.1002/acn3.51273 cortex., pathology, atrophy, cortical thickness, individuals, cognition, functioning, decline, EMIF-AD 90+ study, Aβ
Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics Tijms 2020 EMIF https://doi.org/10.1093/brain/awaa325 Alzheimer’s disease; cerebrospinal fluid; proteomics; subtypes.
Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease Ou 2021 EMIF https://doi.org/10.1038/s41598-021-83000-x plasma, csf, bdnf, mutation, huntington's disease, elisa, HD-CSF cohort, biomarker, cerebrospinal fluid,
Onset of Preclinical Alzheimer Disease in Monozygotic Twins Konijnenberg 2021 EMIF https://doi.org/10.1002/ana.26048 csf, amyloid, aggregation, markers, tau, pet, levels, analyses, correlations
White matter microstructure disruption in early stage amyloid pathology Colij 2021 EMIF https://doi.org/10.1002/dad2.12124 Amyloid beta (Aβ); diffusion tensor imaging (DTI); magnetic resonance imaging (MRI); positron emission tomography (PET); preclinical Alzheimer's disease (AD); white matter microstructure.
Replication study of plasma proteins relating to Alzheimer's pathology Shi 2021 EMIF https://doi.org/10.1002/alz.12322 ATN framework, Alzheimer's disease, biomarker, dementia, network analysis, plasma proteomics, replication
Test-Retest Variability of Relative Tracer Delivery Rate as Measured by [11C]PiB Heeman 2021 EMIF https://doi.org/10.1007/s11307-021-01606-z [11C]PiB, Alzheimer’s disease, Cerebral blood flow, Relative tracer delivery, Test-retest variability
TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels Hong 2021 EMIF https://doi.org/10.1002/alz.12330 Alzheimer's disease; biomarker; cerebrospinal fluid; chitinase-3-like protein 1; genome-wide association study; neurofilament light; neurogranin.
Cerebrospinal fluid α synuclein concentrations in patients with positive AD biomarkers and extrapyramidal symptoms Winkel 2021 EMIF https://doi.org/10.1007/s00702-021-02351-x α Synuclein, Alzheimer’s disease, Cerebrospinal fluid, Extrapyramidal symptoms, Biomarker
Plasma amyloid-β oligomerization assay as a pre-screening test for amyloid status Mofard 2021 EMIF https://doi.org/10.1186/s13195-021-00873-w Blood-based biomarker, Plasma Aβ oligomer, Amyloid status, Multimer detection system, Long-term storage
Sex-Specific Metabolic Pathways Were Associated with Alzheimer’s Disease (AD) Endophenotypes in the European Medical Information Framework for AD Multimodal Biomarker Discovery Cohort Xu 2021 EMIF https://doi.org/10.3390/biomedicines9111610 Alzheimer’s disease; blood; metabolic pathway; metabolomics; sex; tryptophan betaine; vanillylmandelate.
Characteristics of subjective cognitive decline associated with amyloid positivity Janssen 2021 EMIF https://doi.org/10.1002/alz.12512 Alzheimer's disease; amyloid; cerebrospinal fluid; positron emission tomography; subjective cognitive decline.
Magnetoencephalography Brain Signatures Relate to Cognition and Cognitive Reserve in the Oldest-Old: The EMIF-AD 90 + Study Griffa 2021 EMIF https://doi.org/10.3389/fnagi.2021.746373 cognition; cognitive reserve; functional connectivity; magnetoencephalography; oldest-old.
Genetically identical twins show comparable tau PET load and spatial distribution Coomans 2022 EMIF https://doi.org/10.1093/brain/awac004 Alzheimer’s disease, tau, PET, twins, genetics, alzheimer's disease, tau, proteins, monozygotic twins, genetics, pathology
Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer’s disease CSF profile of neuronal injury and inflammation Neumann 2022 EMIF https://doi.org/10.1038/s41380-022-01437-6 Diagnostic markers, Genetics, Rare variants, IFFO1, DTNB, NLRC3, SLC22A10, Alzheimer's disease, CSF, neuronal injury, inflammation
CSF proteomic signature predicts progression to Alzheimer's disease dementia Vromen 2022 EMIF https://doi.org/10.1002/trc2.12240 Alzheimer's disease, cerebrospinal fluid, mild cognitive impairment, prognosis, proteomics
Cerebrospinal fluid tau levels are associated with abnormal neuronal plasticity markers in Alzheimer’s disease Visser 2022 EMIF https://doi.org/10.1186/s13024-022-00521-3 Alzheimer's disease, Molecular mechanisms, Biomarker discovery, Heterogeneity, Neuronal plasticity, Cerebrospinal fluid proteomics
Genome-Wide Association Study of Alzheimer’s Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer’s Disease Homann 2022 EMIF https://doi.org/10.3389/fnagi.2022.840651 genome-wide association study, GWAS, X chromosome, Alzheimer’s disease (AD), MRI, imaging, cognitive function
Optimized sample preparation and data analysis for TMT proteomic analysis of cerebrospinal fluid applied to the identification of Alzheimer's disease biomarkers Weiner 2022 EMIF https://doi.org/10.1186/s12014-022-09354-0 Alzheimer’s disease; Biomarkers; Cerebrospinal fluid; Labeling efficiency; Mass spectrometry; Normalization; Sample preparation; Tandem mass tag.
Effects of age, amyloid, sex, and APOE ε4 on the CSF proteome in normal cognition Wesenhagen 2022 EMIF https://doi.org/10.1002/dad2.12286 age, amyloid, sex, APOE ε4, CSF, proteome, cognition
Title Description Type Project  
EMIF-AD multimodal biomarker discovery study (MBD)

The EMIF-AD MBD study aimed to accelerate the discovery of novel diagnostic and prognostic biomarkers for AD and to unravel the underlying pathophysiological mechanisms using existing data and samples. The EMIF-AD MBD includes harmonized and pooled clinical data from 11 cohort studies across Europe and samples (cerebrospinal fluid, plasma, DNA) and MRI scans which were centrally analyzed using different omics techniques (proteomics, metabolomics, genomics). In total, material from 1221 participants was included (n=492 control, n=527 MCI, n=202 AD dementia). Data requests can be submitted via the EMIF-AD Catalogue. For more information, please visit:

http://www.emif.eu/emif-ad-2/

cohort-clinical-emif-4 EMIF
EMIF-AD 90+ study

The EMIF-AD 90+ study aimed to identify factors associated with resilience to cognitive impairment in the oldest-old. The study was conducted at the Amsterdam University Medical Center and at the University of Manchester. At baseline, neuropsychological and clinical data (vascular comorbidities, mood, sleep, physical performance, genetic factors) were collected from 129 participants (n=84 with normal cognition and n=38 with cognitive deficits). Regarding imaging measures: baseline MRI (n=92), Amyloid-PET (n=103) and MEG (n=92) have been collected. In addition, skin biopsies (n=99) and ultrasound of the carotid artery (n=102) are also collected. Currently (Oct 2019), the first annual follow-up measurements have completed in n=129 as of November 2019, with plans for a second annual follow-up 2020. Data requests can be submitted via the EMIF-AD catalogue. For more information, please visit:

http://www.emif.eu/emif-ad-2/

cohort-clinical-emif-5 EMIF
EMIF-AD PreclinAD study

The EMIF-AD PreclinAD study aimed to indentify new risk factors and diagnostic markers for both amyloid pathology and cognitive decline in cognitively normal subjects with or without amyloid pathology. To investigate this, monozygotic twin pairs were included such that genetic and environmental pathways can be identified. For the baseline measurement n=204 cognitively healthy elderly monozygotic twins aged 60 years and older were included from the Manchester and Newcastle Age and Cognitive Performance Research Cohort and the Netherlands Twin Register. At baseline the following measurements were done: neuropsychological examination (n=204), blood sampling (n=204), CSF collection (n=127), ultrasound of the carotid artery (n=102), magnetoencephalography (n=190) and collection of ophthalmological markers (n=198). In n=192 (94%) the following follow-up measures were done after two years: containing a neuropsychological examination (n=191), blood collection (n=192) and CSF sampling (n=103). A second follow-up will be conducted in 2020. Data requests can be submitted via the EMIF-AD catalogue. For more information, please visit:

http://www.emif.eu/emif-ad-2/

cohort-clinical-emif-6 EMIF
EMIF Catalogue

The EMIF Catalogue is designed to allow researchers to find databases which fulfil their particular research study requirements in a quick and easy way. This portal is a dynamic and flexible system which can be easily customised for different purposes and research interests.

The catalogue compromises several neurodegenerative research projects such as: EMIF-Alzheimer’s Disease (EMIF-AD), European Prevention of Alzheimer's Disease (EPAD) and Multiple Sclerosis Data Alliance (MSDA). EMIF-AD itself contains clinical, neuroimaging and -omics datasets from EMIF-AD MBD, 90+ and PreClinAD studies.

All databases are accessible from the link below.

https://emif-catalogue.eu/

dataset-clinical-emif-10 EMIF
Plasma, DNA and CSF from participants of the EMIF-AD Multimodal biomarker discovery study (MBD)

The EMIF-AD MBD study aimed to accelerate the discovery of novel diagnostic and prognostic biomarker for AD and to unravel the underlying pathophysiological mechanisms using existing data and samples. In total, 1221 participants were recruited to the MBD study(n=492 control, n=527 MCI, n=202 AD dementia). Plasma from 1189 participants, DNA from 929 participants and CSF from 775 participants was obtained. For more information please visit:

http://www.emif.eu/emif-ad-2/

biological-samples-clinical-emif-3 EMIF
Blood samples, CSF and skin biopsies from participants of the EMIF-AD 90+ study

The EMIF-AD 90+ study aimed to identify factors associated with resilience to cognitive impairment in the oldest-old, including 84 participants with normal cognition and 38 with cognitive deficits. The first annual follow-up measurements were completed in n=129 as of November 2019, with plans for a second annual follow-up 2020. Biological samples collected are as follows: 104 blood samples, 99 skin biopsies and 36 samples of CSF. For more information, please visit:

http://www.emif.eu/emif-ad-2/

biological-samples-clinical-emif-4 EMIF
Blood and CSF from participants of the EMIF-AD PreclinAD study

The EMIF-AD PreclinAD study aimed to indentify new risk factors and diagnostic markers for both amyloid pathology and cognitive decline in cognitively normal subjects with or without amyloid pathology. To investigate this monozygotic twin pairs were included such that genetic and environmental pathways can be identified. At baseline the following samples were obtained: blood (n=204), CSF (n=127). In n=192 (94%) the following follow-up measures were done after two years: blood collection (n=192) and CSF sampling (n=103). A second follow-up will be conducted in 2020. For more information please visit:

http://www.emif.eu/emif-ad-2/

biological-samples-clinical-emif-5 EMIF
EMIF-AD data Catalogue

The EMIF Platform is an IT platform that allows access to multiple, diverse data sources. The EMIF Catalogue, part of the EMIF platform, allows users to explore population-based and cohort-derived (predominately AD) data sources who have consented to provide such information for the purposes of bona fide researchers wanting to explore potential data partners for studies. The EMIF Platform makes this data available for browsing and allows exploitation in multiple ways by the end user. The EMIF Platform has leveraged data on more then 62 million European adults and children by means of federation of healthcare databases and cohorts from 7 different countries (DK, IT, NL, UK, ES, EE), designed to be representative of the different types of existing data sources (population-based registries, hospital-based databases, cohorts, national registries, biobanks, etc.). For more information, please visit:

https://emif-catalogue.eu

platform-clinical-emif-1 EMIF
Tools for federated EHR analysis

The EMIF-Platform has leveraged data on more then 62 Million European adults and children by means of federation of healthcare databases and cohorts from 7 different countries (DK, IT, NL, UK, ES, EE), designed to be representative of the different types of existing data sources (population-based registries, hospital-based databases, cohorts, national registries, biobanks, etc.). The data is represented in the EMIF Data Catalogue. For more information, please visit:

http://www.emif.eu/emif-catalogue/

platform-clinical-emif-2 EMIF
Procedures for federated data management

IMI have produced a framework to address challenges raised by local governance rules and potential emerging commercial and academic conflicts across the different EMIF contributing EHR databases. Such a framework will involve all database holders/organisations as participants of the EMIF horizontal layer and has the sole aim to identify governance issues of conflicts of interest that require adaptation of technical functionalities. This in turn will help build a framework focussed on enabling health care providers as well as researchers to re-use patient data in such a way it is acceptable to all partners. For more information, please visit:

http://www.emif.eu/wp-content/uploads/2019/01/emif_d10_2_federation_procedures_exec_summary_website.pdf

tools-clinical-emif-2 EMIF
Risk factors for amyloid pathology, predictors for cognitive decline: clinical biology of AD

Trial design in pre-dementia AD is challenging because subjects with pre-dementia AD are difficult to identify and limited information is available on their outcome. The lack of reliable diagnostic and prognostic markers for pre-dementia AD can be explained by the availability of only small-scale ongoing biomarker studies and longitudinal cohorts including these subjects. EMIF has linked this information and unlocked the true potential of these studies. By connecting relevant cohort studies across Europe, EMIF-AD has set up a pan-European platform for large-scale research on biomarkers and risk factors for neurodegenerative disorders. The biomarker discovery activities in EMIF-AD were driven by an extreme phenotype approach, in which decline or biomarker status was used as the end point for biomarker discovery, rather than a clinical diagnosis. Doing so, EMIF-AD has developed new treatment targets, multimodality/omics diagnostic tools and qualification level biomarker datasets suitable for presentation to regulatory authorities prior to approval for use in clinical trials and practice. Finally, prediction rules for cognitive decline in presymptomatic and prodromal AD were developed which will not only improve clinical diagnosis and prognosis, but equally support subject selection and stratification in future clinical trials. These achievements have been possible because EMIF-AD combined both large-scale patient cohorts, linkage with EHR data, and cutting edge biomarker discovery expertise. For more information, please visit: 

https://doi.org/10.1186/s12877-018-0876-2

tools-clinical-emif-3 EMIF

 

Back to list